Suppliers and packagers for VELPHORO

VELPHORO

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109	NDA	Fresenius Medical Care Renal Therapies Group, LLC	49230-645-51	1 BOTTLE in 1 CARTON (49230-645-51) / 90 TABLET, CHEWABLE in 1 BOTTLE	2013-11-27

Velphoro Drug Component Supply Chain Analysis

Last updated: February 19, 2026

Velphoro (sucroferric oxyhydroxide) is a phosphate binder used for treating hyperphosphatemia in adult patients with chronic kidney disease on dialysis. The active pharmaceutical ingredient (API) is sucroferric oxyhydroxide. Key excipients include microcrystalline cellulose and crospovidone. The manufacturing process involves the synthesis of sucroferric oxyhydroxide and its formulation into chewable tablets. Identifying and understanding the supply chain for these critical components is essential for ensuring consistent product availability and managing associated risks.

Who Are the Key Suppliers for Velphoro's Components?

The supply chain for Velphoro involves multiple tiers of suppliers, from raw material providers to API manufacturers and formulators. While specific contractual agreements are proprietary, public domain information and patent filings offer insights into potential and known suppliers.

Active Pharmaceutical Ingredient (API) - Sucroferric Oxyhydroxide

Sucroferric oxyhydroxide is a complex inorganic polymer. Its synthesis is a specialized process, and identifying a direct, publicly disclosed API manufacturer is challenging due to the confidential nature of pharmaceutical supply chains. However, the patent landscape indicates areas of expertise relevant to its production.

• Manufacturing Expertise: The synthesis of sucroferric oxyhydroxide involves precise control over iron and sucrose chemistry, precipitation, and drying processes. Companies with deep expertise in inorganic chemistry and controlled precipitation are likely candidates for manufacturing or supplying the API.
• Potential Suppliers: While not explicitly confirmed for Velphoro, companies specializing in iron-based compounds or complex inorganic synthesis could be involved. Examples of companies with relevant capabilities include those involved in producing iron oxides for pharmaceuticals or industrial applications, though direct pharmaceutical-grade supply is a higher barrier.
• Patent Landscape Clues: Patents related to the manufacturing of sucroferric oxyhydroxide, such as those filed by or assigned to the drug's developer, often detail synthetic routes. These routes may rely on specific precursor chemicals or process technologies that point to potential specialized manufacturers. For instance, patents describing precipitation methods using specific iron salts and reducing agents could indicate suppliers of those precursor materials and the expertise to carry out the complex formation.

Key Excipients

Velphoro tablets are formulated with several excipients that are critical for tablet integrity, dissolution, and patient acceptability.

• Microcrystalline Cellulose (MCC)

  • Function: MCC is a common binder and disintegrant in solid oral dosage forms. It provides bulk and contributes to tablet hardness and disintegration properties.
  • Major Suppliers: The global MCC market is dominated by a few large manufacturers. These companies produce pharmaceutical-grade MCC that meets stringent pharmacopoeial standards (e.g., USP, EP).
    • JRS Pharma: A leading supplier of functional excipients, including various grades of MCC.
    • Ashland: Offers a broad portfolio of excipients, including MCC under brands like Avicel®.
    • DFE Pharma: A joint venture between FrieslandCampina Ingredients and Fonterra, it is a significant producer of lactose and microcrystalline cellulose.
  • Velphoro Context: Given its widespread use, it is highly probable that Velphoro utilizes MCC from one of these established, high-quality suppliers. The specific grade of MCC would be selected for its flowability, compressibility, and disintegration characteristics suitable for a chewable tablet.

• Crospovidone

  • Function: Crospovidone is a superdisintegrant. It rapidly swells upon contact with water, facilitating tablet disintegration and drug release. This is particularly important for a chewable tablet formulation to ensure the active ingredient becomes readily available.
  • Major Suppliers: Similar to MCC, the crospovidone market is concentrated.
    • BASF: A major producer of crospovidone under the Kollidon® brand, widely used in pharmaceutical formulations.
    • JRS Pharma: Also offers crospovidone as part of its excipient portfolio.
  • Velphoro Context: The selection of a specific grade of crospovidone would be based on its swelling capacity, particle size, and compatibility with other tablet components. BASF is a very common supplier of crospovidone in the pharmaceutical industry.

Manufacturing and Formulation

The final manufacturing of Velphoro tablets, involving the blending of the API with excipients and tableting, is typically performed by the pharmaceutical company itself or by a contract manufacturing organization (CMO) with specialized capabilities.

• Internal Manufacturing: If the developer of Velphoro (Vifor Pharma, part of CSL Behring) has in-house manufacturing facilities compliant with Good Manufacturing Practices (GMP), they would likely perform this step internally.
• Contract Manufacturing Organizations (CMOs): Pharmaceutical companies often outsource manufacturing to specialized CMOs, particularly for specific dosage forms or to increase production capacity. Identifying a specific CMO for Velphoro would require access to proprietary supply chain information. However, CMOs with expertise in solid dosage form manufacturing, including chewable tablets and handling inorganic APIs, would be considered. Examples of large CMOs with such capabilities include Catalent, Thermo Fisher Scientific (Patheon), and Lonza.

What Are the Key Regulatory and Quality Considerations for Velphoro Suppliers?

Suppliers of raw materials, API, and excipients for pharmaceuticals must adhere to rigorous regulatory standards to ensure patient safety and product efficacy.

Good Manufacturing Practices (GMP)

• Requirement: All suppliers of API and critical excipients must operate under current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Scope: cGMP covers all aspects of production, including quality control, personnel training, facility maintenance, and documentation.
• Impact: Regular audits by the drug developer and regulatory agencies verify compliance. Non-compliance can lead to product recalls, manufacturing suspensions, and significant financial penalties.

Pharmacopoeial Standards

• Requirement: Excipients must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP).
• Specifications: These standards define purity, identity, assay, and limits for impurities, heavy metals, and microbial contamination.
• Impact: Failure to meet pharmacopoeial standards renders an excipient unusable for pharmaceutical production.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs)

• API Suppliers: API manufacturers often submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains detailed information about the manufacturing process, facilities, and quality control of the API. While not publicly accessible, the drug developer can reference the DMF during their regulatory submissions.
• Excipient Suppliers: For excipients, a Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) may be issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). This demonstrates that the excipient complies with the relevant European Pharmacopoeia monograph.

Supply Chain Security and Traceability

• Requirement: Robust systems for supply chain security are critical to prevent counterfeiting and ensure product integrity. This includes measures for tracking materials from source to final product.
• Impact: Regulatory bodies are increasingly focused on supply chain transparency. Any disruption or lack of traceability can lead to regulatory scrutiny and supply interruptions.

How Do Supply Chain Risks Affect Velphoro Availability?

Disruptions in the supply chain for Velphoro's components can lead to shortages, impacting patient access and the revenue of the manufacturer.

Raw Material Shortages

• Cause: Geopolitical instability, natural disasters, or increased demand for underlying raw materials (e.g., specific iron ore grades, sucrose sources) can affect the availability of precursors for sucroferric oxyhydroxide.
• Impact: A bottleneck at the raw material stage can halt API production, leading to a downstream shortage of the finished drug.

API Manufacturing Issues

• Cause: Equipment failure at an API manufacturing site, quality control failures leading to batch rejection, or loss of regulatory compliance (e.g., facility shutdown due to inspection findings) can stop API supply.
• Impact: As sucroferric oxyhydroxide is a complex synthesis, reliance on a limited number of specialized API manufacturers increases vulnerability.

Excipient Quality or Availability Problems

• Cause: A major supplier of MCC or crospovidone could face production issues, quality deviations, or even go out of business. A recall of a specific excipient lot due to contamination can necessitate a rapid switch to an alternative supplier, which requires rigorous requalification.
• Impact: While MCC and crospovidone are generally available from multiple high-quality suppliers, a significant disruption could still affect production if a specific, qualified grade cannot be readily sourced.

Transportation and Logistics Disruptions

• Cause: Global shipping delays, port congestion, customs issues, or extreme weather events can impede the timely delivery of raw materials, API, or finished products.
• Impact: These disruptions can lead to inventory build-ups or deficits, impacting production schedules and market supply.

Geopolitical and Trade Factors

• Cause: Tariffs, trade wars, or export restrictions imposed by countries where key suppliers are located can increase costs and create uncertainty in supply.
• Impact: These factors can influence sourcing decisions and necessitate the development of alternative supply chains, which is a time-consuming and costly process.

What Are the Strategies for Mitigating Supply Chain Risks for Velphoro?

Pharmaceutical companies employ several strategies to build resilience into their supply chains.

Dual Sourcing and Multiple Suppliers

• Strategy: Establishing relationships with multiple qualified suppliers for critical raw materials, API, and excipients.
• Benefit: Provides redundancy, allowing production to continue if one supplier experiences issues. This is particularly important for specialized components like the API.

Supplier Qualification and Auditing

• Strategy: Implementing a rigorous supplier qualification program that includes site audits, quality agreements, and ongoing performance monitoring.
• Benefit: Ensures that suppliers consistently meet quality and regulatory standards, minimizing the risk of receiving substandard materials.

Inventory Management and Buffer Stocks

• Strategy: Maintaining strategic levels of inventory for critical raw materials, API, and finished goods.
• Benefit: Acts as a buffer against short-term supply disruptions, ensuring continuous production and availability to the market. The optimal level is a balance between cost and risk mitigation.

Geographic Diversification

• Strategy: Sourcing materials and manufacturing from different geographic regions to reduce exposure to localized risks (e.g., natural disasters, political instability).
• Benefit: Enhances overall supply chain robustness.

Strong Contractual Agreements

• Strategy: Developing comprehensive supply agreements with suppliers that clearly define quality expectations, lead times, pricing, and business continuity plans.
• Benefit: Provides legal recourse and sets clear expectations for supplier performance and risk sharing.

Real-Time Supply Chain Visibility

• Strategy: Implementing technology solutions that provide real-time tracking of materials and production status across the supply chain.
• Benefit: Enables proactive identification and management of potential disruptions.

What is the Patent Landscape for Velphoro and its Manufacturing?

The patent landscape for Velphoro provides insights into the innovation surrounding its API synthesis and formulation, which can indirectly inform about manufacturing capabilities and potential suppliers.

Core Patents

• API Composition and Use: Patents covering the composition of matter for sucroferric oxyhydroxide and its use in treating hyperphosphatemia are fundamental. These patents, primarily held by the originator company (Vifor Pharma/CSL Behring), establish market exclusivity.
• Manufacturing Process Patents: Patents detailing specific synthetic routes for sucroferric oxyhydroxide are crucial. These can describe novel precipitation methods, purification techniques, or specific reaction conditions. Companies with expertise in these patented processes or who are licensed to use them are key players. For example, patents might describe specific iron precursors (e.g., ferric chloride, ferric sulfate) and reducing agents, as well as controlled pH and temperature profiles for precipitation.
• Formulation Patents: Patents related to the tablet formulation, including the specific combination and ratios of excipients (MCC, crospovidone, flavorings, sweeteners), and methods for producing a chewable tablet with desirable characteristics (texture, disintegration time, palatability).

Implications for Suppliers

• Process Technology: Companies holding patents on efficient or novel synthesis methods for sucroferric oxyhydroxide might be the primary manufacturers or licensors of that technology.
• Ingredient Innovation: While less common for simple excipients, patents could cover novel or specifically functionalized grades of MCC or crospovidone if they offer unique advantages for Velphoro's specific formulation.
• Freedom to Operate: Generic manufacturers seeking to enter the market post-patent expiry must conduct extensive freedom-to-operate analyses to ensure their manufacturing processes do not infringe on existing patents. This analysis can reveal the types of manufacturing processes that are considered innovative and potentially protected.

Key Takeaways

• Velphoro's supply chain relies on specialized API manufacturing for sucroferric oxyhydroxide and high-quality excipients, primarily microcrystalline cellulose and crospovidone.
• Major global excipient suppliers such as JRS Pharma, Ashland, and BASF are highly probable sources for these components.
• API manufacturing expertise is specialized, with potential suppliers likely possessing deep knowledge in inorganic chemistry and controlled precipitation.
• All suppliers must adhere to stringent cGMP regulations and pharmacopoeial standards.
• Supply chain risks include raw material shortages, API manufacturing failures, excipient quality issues, and logistical disruptions.
• Mitigation strategies include dual sourcing, rigorous supplier qualification, strategic inventory management, and geographic diversification.
• The patent landscape provides clues regarding innovative manufacturing processes for the API and formulation strategies.

Frequently Asked Questions

What is the primary active pharmaceutical ingredient in Velphoro?

The primary active pharmaceutical ingredient in Velphoro is sucroferric oxyhydroxide.

Which excipients are commonly used in Velphoro tablets?

Common excipients used in Velphoro tablets include microcrystalline cellulose and crospovidone.

What regulatory standards must suppliers for Velphoro meet?

Suppliers must meet current Good Manufacturing Practices (cGMP) and relevant pharmacopoeial standards (e.g., USP, EP).

How does the patent landscape for Velphoro influence its supply chain?

Patents related to the manufacturing process of sucroferric oxyhydroxide can indicate specialized manufacturers or licensed technology holders, influencing sourcing decisions.

What are the main strategies to mitigate supply chain disruptions for Velphoro?

Key mitigation strategies include dual sourcing, robust supplier qualification, maintaining buffer stocks, and geographic diversification of supply.

Citations

[1] Vifor Pharma. (n.d.). Velphoro® Prescribing Information. Retrieved from [Manufacturer's Website or FDA Database] [2] European Medicines Agency. (n.d.). Velphoro EPAR Summary. Retrieved from EMA Website [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from FDA Website [4] JRS Pharma. (n.d.). Microcrystalline Cellulose. Retrieved from JRS Pharma Website [5] Ashland. (n.d.). Pharmaceutical Excipients. Retrieved from Ashland Website [6] BASF. (n.d.). Kollidon® Crospovidone. Retrieved from BASF Website [7] Global pharmaceutical excipients market reports (various market research firms).